• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Vor Biopharma Inc. - Common Stock (NQ:VOR)

    29.34 +0.28 (+0.95%)
    Streaming Delayed Price Updated: 3:45 PM EDT, Oct 17, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 532,587
    Open 28.66
    Bid (Size) 29.27 (2)
    Ask (Size) 29.40 (2)
    Prev. Close 29.06
    Today's Range 28.65 - 31.31
    52wk Range 2.622 - 65.80
    Shares Outstanding 66,956,800
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
    From Vor Biopharma
    Via GlobeNewswire
    Novartis Strengthens Kidney Disease Pipeline With Promising Data
    Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
    Via Benzinga

    Performance

    YTD
    +31.0%
    +31.0%
    1 Month
    -6.6%
    -6.6%
    3 Month
    -38.4%
    -38.4%
    6 Month
    +125.7%
    +125.7%
    1 Year
    +117.2%
    +117.2%

    More News

    Read More
    Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening
    Via Stocktwits
    Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears
    Via Benzinga
    Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel
    From Vor Biopharma
    Via GlobeNewswire
    FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
    Via Benzinga
    Vor Bio's Investigational Drug Scores Phase 3 Win In Autoimmune Kidney Disease Trial
    Via Benzinga
    Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio to Participate in Upcoming Investor Conferences
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate
    Via Benzinga
    Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Vor Biopharma
    Via GlobeNewswire
    Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
    From Vor Biopharma
    Via GlobeNewswire

    Frequently Asked Questions

    Is Vor Biopharma Inc. - Common Stock publicly traded?
    Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
    What exchange does Vor Biopharma Inc. - Common Stock trade on?
    Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
    The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
    What is the current price of Vor Biopharma Inc. - Common Stock?
    The current price of Vor Biopharma Inc. - Common Stock is 29.34
    When was Vor Biopharma Inc. - Common Stock last traded?
    The last trade of Vor Biopharma Inc. - Common Stock was at 10/17/25 03:45 PM ET
    What is the market capitalization of Vor Biopharma Inc. - Common Stock?
    The market capitalization of Vor Biopharma Inc. - Common Stock is 1.96B
    How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
    Vor Biopharma Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.